Mark E. Bunnage, EVP, Chief Scientific Officer: Vertex Pharmaceuticals VRTX Sell · Filed 02/12

Trade details

Type: Insider sale
Amount: $930,529.03
Shares · price: 2,021 sh · $460.43 a share
Held after: 12,914 sh
Stock: Vertex Pharmaceuticals VRTX
Person: Mark E. BunnageEVP, Chief Scientific Officer
Trade date: 26/02/11
Filed: 26/02/12
Days to filing: 1 days

Sold 13.5% of holdings

Share of holding sold: 13.5%

Vertex Pharmaceuticals trades, last 26 weeks

What else happened in Vertex Pharmaceuticals around then

Filed or reported within 30 days of the trade day · 01/12~03/13

Mark E. Bunnage's recent trades

Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$15K
33 sh
$15K
Filed 05/19
Traded 05/15
Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$15K
33 sh
$15K
Filed 05/15
Traded 05/15
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$301.5K
620 sh
$301.5K
Filed 02/26
Traded 02/25
Mark E. BunnageEVP, Chief Scientific Officer
Planned sale10b5-1 planVertex Pharmaceuticals
Planned sale10b5-1 plan
Vertex Pharmaceuticals
VRTX
$301.5K
620 sh
$301.5K
Filed 02/25
Traded 02/25
Mark E. BunnageEVP, Chief Scientific Officer
Sell10b5-1 planVertex Pharmaceuticals
Sell10b5-1 plan
Vertex Pharmaceuticals
VRTX
$1.2M
2,437 sh
$1.2M
Filed 02/19
Traded 02/17